(A) Overall survival of de novo or minimally treated Ph⁺ ALL with the hyper-CVAD and imatinib regimen compared with historic experience with hyper-CVAD alone. (B) Survival by allogeneic stem cell transplantation in first CR after therapy with hyper-CVAD and imatinib. (C) Disease-free survival by age after therapy with hyper-CVAD and imatinib.